Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 cou...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2009
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2795431/
https://ncbi.nlm.nih.gov/pubmed/19904263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605411
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items